DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The "Depression - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Depression - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 33, 30, 76, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

This pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Depression - Overview Depression - Therapeutics Development Depression - Therapeutics Assessment Depression - Companies Involved in Therapeutics Development Depression - Drug Profiles Depression - Dormant Projects Depression - Discontinued Products Depression - Product Development Milestones Companies FeaturedAcadia Pharmaceuticals IncAche Laboratorios Farmaceuticos SAAdamed Sp z ooAddex Therapeutics LtdAequus Pharmaceuticals IncAlbany Molecular Research IncBioXcel Therapeutics IncBristol-Myers Squibb CoCalico LLCCelgene CorpCellix Bio Pvt LtdCelon Pharma SACerecor IncEisai Co LtdEli Lilly and CoIntra-Cellular Therapies IncJiangsu Nhwa Pharmaceutical Corp LtdJohnson & JohnsonKaruna Pharmaceuticals IncKemPharm IncKissei Pharmaceutical Co LtdLead Discovery Center GmbHLuye Pharma Group LtdMedlab Clinical LtdMeta-IQ ApSMitsubishi Tanabe Pharma CorpNavitor Pharmaceuticals IncNeuralstem IncNeurocrine Biosciences IncRichter Gedeon NyrtSage Therapeutics IncShenox Pharmaceuticals LLCSK Biopharmaceuticals Co LtdZysis Ltdand many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pdq5dx/depression?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180913006043/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/13/2018 04:07 PM/DISC: 09/13/2018 04:07 PM

http://www.businesswire.com/news/home/20180913006043/en